Patents Assigned to Celltech R & D Limited
-
Publication number: 20070191608Abstract: This invention provides a class of 3-amino-7H-thieno[2,3-b]pyridin-6-one derivatives, substituted in the 7-position by an aryl, heteroaryl, cycloalkyl or heterocycloalkyl moiety, and in the 2-position by a specified range of substituent groups; also provided is a process for preparing those compounds, and the use thereof as intermediates in the manufacture of certain p38 MAP kinase inhibitors.Type: ApplicationFiled: June 18, 2004Publication date: August 16, 2007Applicant: CELLTECH R&D LIMITEDInventors: Graham Evans, Ian Smith, Neil Tremayne, Leighton Jones, Marianne Langston
-
Patent number: 7244615Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positons (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.Type: GrantFiled: November 7, 2003Date of Patent: July 17, 2007Assignee: Celltech R&D LimitedInventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
-
Patent number: 7244832Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positons (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.Type: GrantFiled: November 7, 2003Date of Patent: July 17, 2007Assignee: Celltech R&D LimitedInventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
-
Patent number: 7244587Abstract: Expression vectors encoding bacteriophage signal peptides are described. The vectors may be used for the heterologous expression and secretion of polypeptides such as antibodies in bacterial host cells.Type: GrantFiled: July 5, 2002Date of Patent: July 17, 2007Assignee: Celltech R&D LimitedInventor: David Paul Humphreys
-
Patent number: 7241877Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.Type: GrantFiled: November 7, 2003Date of Patent: July 10, 2007Assignee: Celltech R&D LimitedInventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
-
Publication number: 20070148172Abstract: The present invention provides a method for the treatment and/or prophylaxis of inflammatory bowel disease (IBD) comprising administering a therapeutically effective amount of an inhibitor of CSF-1 activity.Type: ApplicationFiled: November 3, 2004Publication date: June 28, 2007Applicant: Celltech R & D LimitedInventors: Alastair Lawson, Timothy Bourne
-
Publication number: 20070099894Abstract: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-1-yl or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.Type: ApplicationFiled: June 18, 2004Publication date: May 3, 2007Applicant: Celltech R&D LimitedInventor: Barry Langham
-
Publication number: 20070078131Abstract: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 3-position by an arylcarbonyl or heteroaryl-carbonyl moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.Type: ApplicationFiled: October 22, 2004Publication date: April 5, 2007Applicant: Celltech R&D LimitedInventor: Rikki Alexander
-
Publication number: 20070059307Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.Type: ApplicationFiled: September 11, 2006Publication date: March 15, 2007Applicant: Celltech R&D LimitedInventors: Andrew Popplewell, Simon Tickle, Heather Ladyman
-
Patent number: 7176215Abstract: Compounds of formulae (1a) and (1b) are described: in which the dashed line represents an optional bond; A is a —N? atom or a —N(Rb)—, —C(Rb)? or —C(Rb)(RC)— group; Ra, Rb and Rc is each independently a hydrogen atom or an optionally substituted C1-6alkyl group; X is an —O— or —S— atom or —NH— group or substituted N atom; each Y is independently a N atom or CH group or substituted C atom; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof; The compounds are potent inhibitors of p38 kinase and are use in the prophylaxis or treatment of p38 kinase mediated diseases or disorders, such as rheumatoid arthritisType: GrantFiled: October 16, 2002Date of Patent: February 13, 2007Assignee: Celltech R&D LimitedInventors: Jeremy Martin Davis, Daniel Christopher Brookings, Barry John Langham
-
Publication number: 20070014802Abstract: The present invention relates to a new class of antibody fragments including antibody Fab and Fab? fragments in which the heavy chain is not covalently bonded to the light chain and two or more effector molecules are attached to the fragment, of which at least one of said molecules is attached to a cysteine in the heavy or light chain constant region.Type: ApplicationFiled: July 1, 2004Publication date: January 18, 2007Applicant: Celltech R & D LimitedInventors: Sam Philip Heywood, David Humphreys
-
Publication number: 20070009508Abstract: The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognises an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen.Type: ApplicationFiled: August 12, 2004Publication date: January 11, 2007Applicant: CELLTECH R& D LIMITEDInventors: Alastair Lawson, Meryn Griffiths
-
Publication number: 20070009959Abstract: The invention relates to a method of obtaining an antibody with a desired function, the method comprising: a) bringing a population of B cells into contact with a capturing agent; b) separating the captured B cells from the uncaptured B cells; c) culturing a plurality of captured B cells wherein said B cells have not been sorted into single B cells immediately prior to culturing; d) screening a plurality of the cultured cells to identify cells capable of producing an antibody with the desired function; and e) obtaining the desired antibody therefrom.Type: ApplicationFiled: May 24, 2004Publication date: January 11, 2007Applicant: Celltech R &D LimitedInventors: Alastair David Lawson, Daniel Lightwood
-
Publication number: 20060276507Abstract: A class of piperidine and related heterocyclic derivatives, C-substituted by a substituted aryl or heteroaryl moiety, and N-substituted by an ethylsulfonyl group which in turn is substituted at the 2-position by a hydroxamic acid moiety and also by a range of alternative substituents, being potent inhibitors of CD23 shedding, are useful in the treatment and/or prevention of allergic, inflammatory and neoplastic diseases.Type: ApplicationFiled: June 18, 2004Publication date: December 7, 2006Applicant: Celltech R&D LimitedInventors: David Owen, Robert Watson, Daniel Allen, Andrew Sharpe, Hazel Dyke
-
Publication number: 20060257394Abstract: The present invention provides antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1. Also provided are antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1 to which one or more effector molecules are attached.Type: ApplicationFiled: July 1, 2004Publication date: November 16, 2006Applicant: Celltech R&D LimitedInventors: David Humprheys, Sam Heywood
-
Publication number: 20060241118Abstract: A class of piperazine and related heterocyclic derivatives, substituted at the 4-position by a substituted aryl or heteroaryl moiety, and at the 1-position by an ethylsulfonyl group which in turn is substituted at the 2-position by a hydroxamic acid moiety and also by a range of alternative substituents, being potent inhibitors of CD23 shedding, are useful in the treatment and/or prevention of allergic, inflammatory and neoplastic diseases.Type: ApplicationFiled: June 18, 2004Publication date: October 26, 2006Applicant: Celltech R&D LimitedInventors: David Owen, Robert Watson, Daniel Allen, Andrew Sharpe, Hazel Dyke
-
Patent number: 7122556Abstract: Phenylalanine enamide derivatives of formula (1) are described: wherein R1 is a group Ar1L2Ar2Alk— in which: Ar1 is an optionally substituted aromatic or heteroaromatic group; L2 is a covalent bond or a linker atom or group; Ar2 is an optionally substituted arylene or heteroarylene group; and Alk is a chain in which R is a carboxylic acid (—CO2H) or a derivative or biostere thereof; X is an —O— or —S— atom or —N(R2)— group in which: Rx, Ry and Rz which may be the same or different is each a hydrogen atom or an optional substituent; or Rz is an atom or group as previously defined and Rx and Ry are joined together to form an optionally substituted spiro linked cycloaliphatic or heterocycloaliphatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.Type: GrantFiled: September 22, 2004Date of Patent: October 17, 2006Assignee: Celltech R&D LimitedInventors: Stephen Brand, Stuart Bailey, Julien A. Brown, James A. Johnson, John R. Porter, John C. Head
-
Publication number: 20060171940Abstract: The present invention relates to disulfide isomers of an antibody having specificity for antigenic determinants of human tumor necrosis factor alpha (TNF?). The present invention also relates to compositions comprising the isomers and therapeutic uses of the antibody. The present invention also relates to analytical methods of detecting the TNF? antibody disulfide isomers and oxidated methionyl forms of the TNF? antibodies.Type: ApplicationFiled: March 20, 2003Publication date: August 3, 2006Applicant: Celltech R&D LimitedInventors: Ned Mozier, Robert Dufield, Jianming Mo, Gary Bild
-
Publication number: 20060148012Abstract: The present invention provides a homogeneous assay for identifying an antibody producing cell producing an antibody which binds to a selected antigen comprising: a) providing a population of antibody producing cells; b) incubating said population of antibody producing cells with a selected antigen and a labeled anti-antibody antibody, wherein said anti-antibody antibody is capable of distinguishing cells producing an antibody which binds to the selected antigen from those cells which do not; and c) identifying an antibody producing cell capable of producing an antibody which binds to the selected antigen.Type: ApplicationFiled: December 1, 2003Publication date: July 6, 2006Applicant: Celltech R&D LimitedInventors: Derek Brown, Lisa Butler, Karen Cromie, Meryn Griffiths, Alstair Lawson, Daniel Lightwood
-
Patent number: RE39548Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.Type: GrantFiled: December 7, 2001Date of Patent: April 3, 2007Assignee: Celltech R&D LimitedInventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage